AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 180 filers reported holding AERIE PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 0.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,458,000 | +401.2% | 228,542 | +148.5% | 0.00% | – |
| Q2 2022 | $690,000 | -18.2% | 91,957 | -0.8% | 0.00% | – |
| Q1 2022 | $844,000 | +157.3% | 92,732 | +98.2% | 0.00% | – |
| Q4 2021 | $328,000 | -96.0% | 46,781 | -93.5% | 0.00% | -100.0% |
| Q3 2021 | $8,177,000 | +454.4% | 717,281 | +678.5% | 0.00% | – |
| Q2 2021 | $1,475,000 | -22.5% | 92,135 | -13.5% | 0.00% | – |
| Q1 2021 | $1,904,000 | -67.9% | 106,540 | -75.7% | 0.00% | -100.0% |
| Q4 2020 | $5,928,000 | -46.4% | 438,755 | -53.4% | 0.00% | -66.7% |
| Q3 2020 | $11,070,000 | -56.6% | 940,530 | -45.5% | 0.00% | -66.7% |
| Q2 2020 | $25,487,000 | +371.3% | 1,726,775 | +331.0% | 0.01% | +350.0% |
| Q1 2020 | $5,408,000 | -76.5% | 400,637 | -57.9% | 0.00% | -80.0% |
| Q4 2019 | $22,991,000 | +147.0% | 951,192 | +96.4% | 0.01% | +100.0% |
| Q3 2019 | $9,307,000 | +80.2% | 484,271 | +177.0% | 0.01% | +150.0% |
| Q2 2019 | $5,165,000 | -73.6% | 174,801 | -57.5% | 0.00% | -81.8% |
| Q1 2019 | $19,540,000 | -66.2% | 411,360 | -74.3% | 0.01% | -64.5% |
| Q4 2018 | $57,855,000 | -36.0% | 1,602,630 | +9.1% | 0.03% | -24.4% |
| Q3 2018 | $90,407,000 | +2620.6% | 1,468,829 | +2885.2% | 0.04% | +1950.0% |
| Q2 2018 | $3,323,000 | +92.2% | 49,204 | +54.4% | 0.00% | – |
| Q1 2018 | $1,729,000 | -63.0% | 31,861 | -59.3% | 0.00% | -100.0% |
| Q4 2017 | $4,672,000 | -65.2% | 78,203 | -71.7% | 0.00% | -72.7% |
| Q3 2017 | $13,435,000 | +56.3% | 276,421 | +69.0% | 0.01% | +57.1% |
| Q2 2017 | $8,595,000 | -56.7% | 163,559 | -62.7% | 0.01% | -61.1% |
| Q1 2017 | $19,872,000 | -54.1% | 438,189 | -61.7% | 0.02% | -58.1% |
| Q4 2016 | $43,255,000 | +79.3% | 1,142,795 | +78.8% | 0.04% | +79.2% |
| Q3 2016 | $24,123,000 | +15265.0% | 639,154 | +4848.2% | 0.02% | – |
| Q1 2016 | $157,000 | -28.6% | 12,917 | +4.1% | 0.00% | – |
| Q3 2015 | $220,000 | +155.8% | 12,403 | +155.7% | 0.00% | – |
| Q2 2015 | $86,000 | – | 4,851 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
| LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
| DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
| DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
| Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
| PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
| Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |